There have been previous studies showing the benefit of aspirin as an anti-cancer agent, particularly for colorectal adenomas. This study from the Lancet looks at its use in preventing colorectal cancer itself in those at higher risk (carriers of Lynch syndrome).
861 patients altogether, randomly assigned to either aspirin or placebo, followed up for over 4 years. The overall hazard ratio was 0.63 in favour of asporin, with the numbers only getting stronger with longer follow up. There was no increase in adverse events either during intervention.
Important to note the dose of aspirin here – 600mg daily, for at least 2 years – but the mechanism and concept is certainly interesting. Check it out over here.source | The Lancet image | Chaval Brasil